Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products
Pharmaceutical giants are pouring tens of millions of pounds into struggling NHS services – including paying the salaries of medical staff and funding the redesign of patient treatment – as they seek to boost drug sales in the UK, the Observer can reveal.
Drug firms are simultaneously funding groups that lobby for greater investment in their disease areas, and in some cases are paying generous consultancy fees to influential healthcare professionals, including GPs who have worked as clinical leads for NHS England and have received as much as £480,000 each from industry since 2019.
